Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Total HIV Franchise Product Sales by Quarter
Total HIV Franchise Product Sales — Worldwide YoY growth (%) (%)
Gilead Sciences Total HIV Franchise Product Sales: 12.0% in Q2 2026, up 5.0 pts from a year earlier.
Latest, Q2 2026
12.0%
Period ended Jun 30, 2026
Change on a year earlier
+5.0 pts
7.0% in Q2 2025
History
22 quarters
Since Q1 2021
Sources
22
Documents cited below
Where the Q2 2026 figure comes from
“|| HIV | $ | 5,693 | $ | 5,088 | 12% | $ | 10,723 | $ | 9,675 | 11%”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Reported in Form 8-K Total Revenue Summary.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Gilead Sciences Total HIV Franchise Product Sales (%), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/hiv-total-yoy
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.